Global biotechnology company Dyadic Applied BioSolutions has announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals and Inzymes ApS. The company, which produces precision-engineered, animal-free proteins and enzymes for commercial applications, has also provided updates on its business transformation and commercial progress.
In food and nutrition, Dyadic has announced the signing of a term sheet for the development of non-animal human alpha-lactalbumin for use in the infant nutrition market. Initial sampling of the ingredient is in progress, and licensing discussions are underway with potential partners.
Additionally, Dyadic has received a $250,000 milestone payment through its partnership with Inzymes, following the achievement of productivity improvements for its non-animal dairy enzymes in Q3 2025. One enzyme is expected to launch later this year, and others are also advancing as part of the collaboration.
Life sciences
In life sciences, Dyadic has reached a productivity milestone in the development of recombinant human albumin, and will receive a $500,000 payment through its partnership with Proliant. The latter company has started sampling the product, and a commercial launch is targeted for late 2025 and early 2026.
Initial production of Dyadic’s lab-grade non-animal transferrin products is also underway, meeting OEM and supply opportunities. Sampling efforts are expanding in the cultivated meat, research, and diagnostic markets, while validation is ongoing with research and diagnostic customers.
Furthermore, Dyadic’s DNase I has met the required performance benchmarks for activity and purity, validating its use in molecular biology, diagnostics, and biopharma applications. The company is currently producing the DNase I at research grade, supporting direct sales and OEM supply opportunities.
“Substantial progress throughout our portfolio”
In 2023, an independent analysis confirmed that Dyadic’s animal-free bovine serum albumin (BSA) was structurally identical to commercial animal albumin, opening up new commercialization opportunities. BSA is widely used in the pharmaceutical industry and is the main constituent of fetal bovine serum, often used for cell growth in cultivated meat.
“Dyadic is advancing its transition to a commercially focused, revenue-driven company,” said Joe Hazelton, Dyadic Applied BioSolutions President and Chief Operating Officer. “The third quarter featured substantial progress throughout our portfolio, marked by notable achievements in partnerships with Proliant Health and Biologicals in the life sciences sector, as well as ongoing collaborations with Inzymes in food and nutrition.
“These accomplishments highlight the versatility and scalability of Dyadic’s protein production platforms across multiple markets. The company remains committed to capitalizing on near-term commercialization opportunities, supported by a stronger balance sheet and an expanding pipeline of both partner-led and internally developed products.”
